Business
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
RAHWAY, N.J., March 18, 2026--Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), today announced the U.S. Food and Drug Administration (FDA) approved an expanded label for BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) in dogs. The updated indication adds treatment and control of Asian longhorned tick (H. longicornis) and Gulf Coast tick (A. maculatum) for 12 months, when
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":240,"url":"https://media.zenfs.com/en/business-wire.com/47a968517afec139da18f057bf352994"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L_oEJ2VKUJj7Hb4wPsiK9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/47a968517afec139da18f057bf352994","width":480,"height":240}},"lazy":false},{"type":"text","content":"Expanded label for once-yearly parasiticide treatment for dogs now includes Haemaphysalis longicornis (Asian longhorned tick) and Amblyomma maculatum (Gulf Coast tick) for 12 months","length":181,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J., March 18, 2026--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), today announced the U.S. Food and Drug Administration (FDA) approved an expanded label for BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) in dogs. The updated indication adds treatment and control of Asian longhorned tick (H. longicornis) and Gulf Coast tick (A. maculatum) for 12 months, when administered as a single, veterinarian‑delivered injection.","length":581,"tagName":"p"},{"type":"text","content":"BRAVECTO QUANTUM was approved in the U.S. on July 10, 2025, and continues to be indicated to kill adult fleas, for the treatment and prevention of flea infestations, and for the treatment and control of Ixodes scapularis, Dermacentor variabilis, and Rhipicephalus sanguineus infestations for 12 months and A. americanum infestations for 8 months in dogs and puppies 6 months of age and older.","length":392,"tagName":"p"},{"type":"text","content":""For more than a decade, BRAVECTO has set the benchmark for extended‑duration flea and tick protection, and today’s label expansion reinforces our leadership in parasiticide innovation," said Meg Conlon, DVM, executive director, U.S. Companion Animal Veterinary Services, Merck Animal Health. "With BRAVECTO QUANTUM, Merck Animal Health continues to deliver the longest‑lasting protection available in a single dose – now covering an even broader range of clinically important tick species. This advancement reflec...